Journal of Leukemia
Open Access

Exploring the Role of Natural Killer Cell Receptors and HLA Ligands in Diffuse Large B-Cell Lymphoma Treatment: Potential Targets for Novel Therapies

Daniela Maira Cardozo^1*, Marangon Amanda Vansan¹, Guimarães Fernando¹, Visentainer Jeane² and De Souza Cármino^{1 *}Correspondence: Daniela Maira Cardozo, Department of Medical Sciences, State University of Campinas, Rua Carlos Chagas,, Brazil, Email:

Author info »

Introduction

Non-Hodgkin lymphoma is the most common hematologic neoplasm worldwide. Diffuse Large B-Cell Lymphoma is the most aggressive subtype of NHL, with a diffuse growth pattern and high rates of relapse after first-line treatment (around 20%-50% of patients within a 5-year period) [1-2].

The most common first-line treatment for Diffuse Large B Cell Lymphoma (DLBCL) is Rituximab-Cyclophosphamide- Hydroxydaunorubicin-Oncovin-Prednisone (R-CHOP), which is a combination of cyclophosphamide, doxorubicin, vincristine, and the anti-CD20 monoclonal antibody known as rituximab. The introduction of rituximab to combined therapy with CHOP has improved Overall Survival (OS) and Progression-Free Survival (PFS) for patients with B-cell derived hematologic diseases. However, many DLBCL patients do not respond to RCHOP, and in these cases, treatment options become increasingly limited [3].

Despite recent studies showing promising alternative treatments for DLBCL patients, such as cell therapy with T cells genetically modified with Chimeric Antigen Receptors (CAR-T), for the vast majority of centers, R-CHOP will remain the first available line of treatment for many years to come [4].

The main mechanism of action of rituximab is the activation of Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC). In this case, the Fc portion of the anti-CD20 Monoclonal Antibody (mAb) is recognized by a receptor expressed on the surface of an effector cell that opsonizes these cells, promoting the binding of anti-CD20 to CD20 expressed on the surface of B cells (normal and modified), leading to the destruction of these lymphocytes through the activation of effector cell cytotoxicity [1].

Literature Review

Natural Killer (NK) cells are considered the main effector cells involved in the activation of ADCC by rituximab. Therefore, it is important to thoroughly study the profile of NK cells in relation to their surface inhibitory and activating receptors, along with their respective ligands, as well as the characteristics of these interactions. Additionally, in the last decade, the number of studies related to the antitumor role of NK cells has shown that these cells are promising in the scenario of Hematopoietic Stem Cell Transplantation (HSCT), allogeneic and haplo identical, as well as in the adoptive transfer of these cells as therapy for some hematological diseases [5-7].

Therefore, the aim of this mini-review is to present the most recent findings related to the role and importance of NK cells, mainly of Killer-Cell Immunoglobulin-Like Receptors (KIR) and their HLA ligands, in the context of treatment, development, and progression of patients with DLBCL.

NK cells are a subset of lymphocytes that express CD56 but not CD3 and play a vital role in the immune system, including involvement in autoimmunity and recognition of tumor cells. In the context of HSCT, donor-derived NK cells can recognize and kill residual leukemia cells and cure malignant patients [8].

The function of NK cells is regulated by many types of expressed receptors. The most important group of them can be represented by KIR receptors (Killer-Cell Immunoglobulin-Like Receptors) that recognize and bind to specific class I HLA molecules expressed on target cells, signaling for the activation/ inhibition pathways and licensing/education of NK cells. Evolutionarily, class I HLA molecules are functionally selected in close correlation with the specificity of KIR genes [9].

Recent evidence suggests that the KIR/HLA interaction may play a role in both the development and progression of DLBCL. Makanga et al. evaluated the impact of KIR genotypes, HLA class I, and CD16 on rituximab-dependent NK cell responses in an in vitro cellular model of healthy blood donors and ex vivo rituximab-treated Non-Hodgkin Lymphoma (NHL). The study describes, for the first time, the triggering effect of the KIR2DS1- C2 interaction on rituximab-dependent NK cell degranulation. Although the triggering effect of KIR2DS1 on the total rituximab-dependent NK cell response is limited due to the low frequency of KIR2DS1+ NK cells, selecting KIR2DS1+C2- NK cells may be advantageous with the overall goal of obtaining a more efficient CD16 lineage for promoting ADCC [10].

Discussion

In addition, the lack of class I HLA ligands for KIR receptors may favor ADCC responses of rituximab-dependent NK cells in patients with NHL. Therefore, class I HLA typing and the frequency of NK cells KIR+ in peripheral blood may be simple and useful markers for predicting response to rituximab [10].

Lisovsky and colleagues demonstrated the contribution of education to antibody-dependent NK cell activation and found that education through KIR3DL1 and KIR2DL1, but not KIR2DL3, enhances antibody-mediated secretion of IFN-γ and CCL4, compared to uneducated cells [11].

Erbe et al. also demonstrated that patients who inherited KIR2DL2 and its ligand (HLA-C1) together with KIR3DL1 and its ligand (HLA-Bw4) had better outcomes compared to patients without this genotype. Furthermore, patients with KIR2DL2 and HLA-C1 together with KIR3DL1 and HLA-Bw4 also showed better duration of response and tumor reduction during maintenance period, while patients without this genotype did not show improvement when receiving maintenance [12].

Kaddu-Mulindwa and colleagues observed that DLBCL patients who were positive for KIR2DS1 and homozygous for HLA-C2 did not benefit from the addition of rituximab to CHOP therapy, further demonstrating that defining KIR/HLA genotypes can be a useful marker for evaluation and decisionmaking regarding treatment [13] .

There is evidence suggesting that in the context of allogeneic Stem Cell Transplantation (SCT), for patients with NHL, the KIR B/x genotype of the donor provides the recipient with better rates of progression-free survival after HLA 10/10 unrelated SCT [14].

Indeed, the latest evidence confirms the importance of the role of KIR receptors and their HLA ligands in the context of treatment of patients with NHL, especially DLBCL, and highlights the importance of understanding the NK cell response to different receptor profiles, which could bring new treatment perspectives for these patients.

As an example, we can mention Chu and colleagues, who suggest that, just like Chimeric Antigen Receptor (CAR-T) cell therapy, NK cells can receive chimeric antigens with the goal of recognizing modified B cells and treating patients with DLBCL [15]. Phase I/II studies have already shown that CAR-NK therapy could be the future of treatment for patients with more aggressive subtypes of NHL such as DLBCL [16-19].

Conclusion

Therefore, we can conclude that the study of NK cells, their activating and inhibitory receptors, as well as their respective ligands can greatly contribute to the establishment of new lines of therapy for patients who do not respond to the treatments available for NHL, especially for DLBCL. Natural Killer (NK) cells are considered the main effector cells involved in the activation of ADCC by rituximab. Therefore, it is important to thoroughly study the profile of NK cells in relation to their surface inhibitory and activating receptors, along with their respective ligands, as well as the characteristics of these interactions. Additionally, in the last decade, the number of studies related to the antitumor role of NK cells has shown that these cells are promising in the scenario of Hematopoietic Stem Cell Transplantation (HSCT), allogeneic and haplo identical, as well as in the adoptive transfer of these cells as therapy for some hematological diseases. The most common first-line treatment for DLBCL is R-CHOP, which is a combination of cyclophosphamide, doxorubicin, vincristine, and the anti-CD20 monoclonal antibody known as rituximab. The introduction of rituximab to combined therapy with CHOP has improved Overall Survival (OS) and Progression-Free Survival (PFS) for patients with B-cell derived hematologic diseases. However, many DLBCL patients do not respond to R-CHOP, and in these cases, treatment options become increasingly limited. In addition, the lack of class I HLA ligands for KIR receptors may favor ADCC responses of rituximab-dependent NK cells in patients with NHL. Therefore, class I HLA typing and the frequency of NK cells KIR+ in peripheral blood may be simple and useful markers for predicting response to rituximab. Recent evidence suggests that the KIR/HLA interaction may play a role in both the development and progression of DLBCL. Makanga et al. evaluated the impact of KIR genotypes, HLA class I, and CD16 on rituximab-dependent NK cell responses in an in vitro cellular model of healthy blood donors and ex vivo rituximabtreated Non-Hodgkin Lymphoma (NHL). The study describes, for the first time, the triggering effect of the KIR2DS1-C2 interaction on rituximab-dependent NK cell degranulation.

Although the triggering effect of KIR2DS1 on the total rituximab-dependent NK cell response is limited due to the low frequency of KIR2DS1+ NK cells, selecting KIR2DS1+C2- NK cells may be advantageous with the overall goal of obtaining a more efficient CD16 lineage for promoting ADCC.

Acknowledgement

This work was supported by Fundação de Pesquisa do Estado de São Paulo (FAPESP), State of São Paulo, Brazil.

Declarations of Interests

The authors declare that there is no conflict of interest.

Authors Statement

Daniela Cardozo: Conceptualization, Methodology, Software, Reviewing and Editing; Amanda Marangon.: Data curation, Writing- Original draft preparation; Fernando Guimarães: Visualization, Investigation and Supervision; Carmino de Souza: Supervision and Project Administration; Jeane Visentainer: Writing- Reviewing and Editing.

References

1. Kusowska A, Kubacz M, Krawczyk M, Slusarczyk A, Winiarska M, Bobrowicz M. Molecular aspects of resistance to immunotherapies-advances in understanding and management of diffuse large b-cell lymphoma. Int J Mol Sci. 2022;23(3):1501.

   [Crossref] [Google Scholar] [PubMed]

2. Shaw J, Harvey C, Richards C, Kim C. Temporal trends in treatment and survival of older adult diffuse large B-Cell lymphoma patients in the SEER-Medicare linked database. Leuk Lymphoma. 2019;60(13):3235-3243.

   [Crossref] [Google Scholar] [PubMed]

3. Salles G, Barrett M, Foà R, Maurer J, O'Brien S, Valente N, et al. Rituximab in B-cell hematologic malignancies: a review of 20 years of clinical experience. Adv Ther. 2017;34(10):2232-2273.

   [Crossref] [Google Scholar] [PubMed]

4. Denlinger N, Bond D, Jaglowski S. CAR T-cell therapy for B-cell lymphoma. Curr Probl Cancer. 2022;46(1):100826.

   [Crossref] [Google Scholar] [PubMed]

5. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002;295:2097-2100.

   [Crossref] [Google Scholar] [PubMed]

6. Giebel S, Locatelli F, Lamparelli T, Velardi A, Davies S, Frumento G, et al. Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood. 2003;102:814-819.

   [Crossref] [Google Scholar] [PubMed]

7. Cardozo DM, Marangon AV, da Silva RF, Aranha FJP, Visentainer JEL, Bonon SHA, et al. Synergistic effect of KIR ligands missing and cytomegalovirus reactivation in improving outcomes of haematopoietic stem cell transplantation from HLA-matched sibling donor for treatment of myeloid malignancies. Hum Immunol. 2016;77(10):861-868.

   [Crossref] [Google Scholar] [PubMed]

8. Gwozdowicz S, Nestorowicz K, Graczyk-Pol E, Szlendak U, Rogatko-Koros M, Mika-Witkowska R, et al. KIR specificity and avidity of standard and unusual C1, C2, Bw4, Bw6 and A3/11 amino acid motifs at entire HLA: KIR interface between NK and target cells, the functional and evolutionary classification of HLA class I molecules. Int J Immunogenet. 2019;46(4):217-231.

   [Crossref] [Google Scholar] [PubMed]

9. Hoseinian SA, Jafari D, Mahmoodi M, Alimoghaddam K, Ostadali M, Talebzadeh Bonakdar A. The impact of donor and recipient KIR genes and KIR ligands on the occurrence of acute graft-versus-host disease and graft survival after HLA-identical sibling hematopoietic stem cell transplantation. Turk J Med Sci. 2018;48(4):794-804.

   [Crossref] [Google Scholar] [PubMed]

10. Makanga DR, Jullien M, David G, Legrand N, Willem C, Dubreuil L, et al. Low number of KIR ligands in lymphoma patients favors a good rituximab-dependent NK cell response. Oncoimmunology. 2021;10(1):1936392.

    [Crossref] [Google Scholar] [PubMed]

11. Lisovsky I, Kant S, Tremblay-McLean A, Isitman G, Kiani Z, Dupuy FP, et al. Differential contribution of education through KIR2DL1, KIR2DL3, and KIR3DL1 to antibody-dependent (AD) NK cell activation and ADCC. J Leukoc Biol. 2019;105(3):551-563.

    [Crossref] [Google Scholar] [PubMed]

12. Erbe AK, Wang W, Carmichael L, Hoefges A, Grzywacz B, Reville PK, et al. Follicular lymphoma patients with KIR2DL2 and KIR3DL1 and their ligands (HLA-C1 and HLA-Bw4) show improved outcome when receiving rituximab. J Immunother Cancer. 2019;7:1-2.

    [Crossref] [Google Scholar] [PubMed]

13. Kaddu-Mulindwa D, Altmann B, Robrecht S, Ziepert M, Regitz E, Tausch E, et al. KIR2DS1-HLA-C status as a predictive marker for benefit from rituximab: a post-hoc analysis of the RICOVER-60 and CLL8 trials. Lancet Haematol. 2022;9(2):e133-e142.

    [Crossref] [Google Scholar] [PubMed]

14. Bachanova V, Weisdorf DJ, Wang T, Marsh SGE, Trachtenberg E, Haagenson MD, et al. Donor KIR B Genotype Improves Progression-Free Survival of Non-Hodgkin Lymphoma Patients Receiving Unrelated Donor Transplantation. Biol Blood Marrow Transplant. 2016;22(9):1602-1607.

    [Crossref] [Google Scholar] [PubMed]

15. Chu Y, Lamb M, Cairo MS, Lee DA. The future of natural killer cell immunotherapy for B Cell Non-Hodgkin Lymphoma (B Cell NHL). Curr Treat Options Oncol. 2022;23(3):381-403.

    [Crossref] [Google Scholar] [PubMed]

16. Universal chimeric antigen receptor-modified at19 cells for cd19+ relapsed/​refractory hematological malignancies. 2021.
17. CAR.CD19-CD28-zeta-2A-iCasp9-IL15-transduced cord blood NK cells, high-dose chemotherapy, and stem cell transplant in treating participants with b-cell lymphoma. 2020.
18. FT596 as a monotherapy and in combination with anti-cd20 monoclonal antibodies. 2023.
19. Study of Anti-CD19 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma. 2019.